Becton, Dickinson and Company filings document the reporting, governance and capital-structure matters of a New York Stock Exchange-listed medical technology issuer. Its Form 8-K disclosures cover quarterly operating results, non-GAAP financial measures, dividend and capital allocation updates, executive appointments, compensatory arrangements and amendments to corporate by-laws.
The filing record also documents BD's completed separation of its Biosciences and Diagnostic Solutions business and related recast historical financial information presenting that business as discontinued operations. Capital-structure disclosures include registered common stock, NYSE-listed notes and tender-offer activity involving senior notes and debentures.
BECTON DICKINSON AND CO ownership update: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 9,673,586 shares of Common Stock, representing 3.4% of the class. The filing lists sole voting power for 9,066,401 shares and sole dispositive power for 9,673,586 shares. The amendment is signed by Ellen York, Vice President, on 05/15/2026.
Becton, Dickinson and Company, through its Luxembourg subsidiary Becton Dickinson Euro Finance S.à r.l., entered into an underwriting agreement to issue €600,000,000 aggregate principal amount of 3.855% Notes due 2033. The new Euro Notes will be fully and unconditionally guaranteed on a senior unsecured basis by BD.
BD and Becton Finance expect to use the net proceeds from this offering, together with cash on hand, to repay the outstanding 1.208% Euro Notes due June 4, 2026, including accrued interest, fees and expenses. Completion of the offering is expected on or about May 20, 2026, subject to customary closing conditions.
Becton Dickinson Euro Finance S.à r.l. proposes a euro-denominated notes offering fully and unconditionally guaranteed by Becton, Dickinson and Company. The prospectus supplement describes annual euro interest, optional redemption mechanics (including a Par Call Date), a change-of-control repurchase at 101% and a tax‑related whole‑notice redemption right. Net proceeds are to be used, together with cash on hand, to repay the Issuer’s 1.208% Euro Notes due June 4, 2026. The notes will be issued in minimum denominations of €100,000, represented by global registered notes held under a common safekeeper for Euroclear and Clearstream, and listing on the NYSE has been requested.
Becton Dickinson & Co director Robert Luther Huffines received 210 derivative rights to common stock under the BD Deferred Compensation Plan. The rights were granted at a reference price of $149.04 per right and increase his total deferred rights to 404.
Each right converts into one share of common stock, and the securities are distributed after his service as a director ends or on dates he previously specified. The total also reflects rights acquired through dividend reinvestment and adjustments related to combining the Biosciences and Diagnostic Solutions businesses with Waters Corp.
Becton Dickinson & Co director Carrie L. Byington received 105 rights to common stock under the BD Deferred Compensation Plan as a compensation-related derivative award. Each right converts into one share of common stock, bringing her total deferred stock rights to 3,699 after this grant.
Becton Dickinson & Co EVP & Chief Financial Officer Vitor Roque received an equity grant. He acquired 1,721 shares of Common Stock on May 7, 2026 through a grant or award at a reported price of $0.00 per share. After this award, he directly holds 8,231 shares, which include restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Becton, Dickinson and Company reported fiscal quarter results for the period ended March 31, 2026 that mix solid revenue growth with significant one‑time charges and a major portfolio change. Continuing operations revenues rose to $4.714 billion from $4.480 billion, driven by 2.4% volume growth and a 2.6% favorable currency impact.
Despite higher sales, BD posted a net loss of $311 million, versus net income of $308 million a year earlier, as earnings were weighed down by discontinued operations and restructuring. Loss from discontinued operations related to the spin‑off of the Biosciences and Diagnostic Solutions business was $274 million for the quarter, while integration, restructuring and transaction expense surged to $533 million, including $450 million of non‑cash asset impairments.
BD completed the spin‑off and Reverse Morris Trust combination of that business with Waters Corporation, receiving a $4 billion cash distribution. The company used $2 billion for an accelerated share repurchase and $2 billion for debt repayments, contributing to long‑term debt falling to $14.706 billion from $17.620 billion. Operating cash flow from continuing operations strengthened to $1.328 billion for the first six months, supporting $589 million of dividends and $2.250 billion of total share repurchases.
Becton, Dickinson and Company reported fiscal quarter results for the period ended March 31, 2026 that mix solid revenue growth with significant one‑time charges and a major portfolio change. Continuing operations revenues rose to $4.714 billion from $4.480 billion, driven by 2.4% volume growth and a 2.6% favorable currency impact.
Despite higher sales, BD posted a net loss of $311 million, versus net income of $308 million a year earlier, as earnings were weighed down by discontinued operations and restructuring. Loss from discontinued operations related to the spin‑off of the Biosciences and Diagnostic Solutions business was $274 million for the quarter, while integration, restructuring and transaction expense surged to $533 million, including $450 million of non‑cash asset impairments.
BD completed the spin‑off and Reverse Morris Trust combination of that business with Waters Corporation, receiving a $4 billion cash distribution. The company used $2 billion for an accelerated share repurchase and $2 billion for debt repayments, contributing to long‑term debt falling to $14.706 billion from $17.620 billion. Operating cash flow from continuing operations strengthened to $1.328 billion for the first six months, supporting $589 million of dividends and $2.250 billion of total share repurchases.
Becton, Dickinson and Company has appointed Vitor Roque as executive vice president and chief financial officer, effective May 7, 2026, following his service as interim CFO since December 2025.
The board set his annual base salary at $770,000, with a target bonus equal to 95% of base salary for the fiscal year ending September 30, 2026, and an annual equity award target of $3,000,000, all effective as of the appointment date. In recognition of his interim CFO service, he will receive a $250,000 cash payment and time‑vested units valued at $250,000 under the company’s 2004 equity plan, subject to continued service. Roque will also enter into a change‑of‑control employment agreement providing a severance multiple of two times salary and bonus, similar to other executive officers, and remains eligible for the company’s standard executive benefit and severance programs. The company states he has no family relationships with directors or executive officers and no related‑party transactions requiring disclosure.
Becton, Dickinson and Company has appointed Vitor Roque as executive vice president and chief financial officer, effective May 7, 2026, following his service as interim CFO since December 2025.
The board set his annual base salary at $770,000, with a target bonus equal to 95% of base salary for the fiscal year ending September 30, 2026, and an annual equity award target of $3,000,000, all effective as of the appointment date. In recognition of his interim CFO service, he will receive a $250,000 cash payment and time‑vested units valued at $250,000 under the company’s 2004 equity plan, subject to continued service. Roque will also enter into a change‑of‑control employment agreement providing a severance multiple of two times salary and bonus, similar to other executive officers, and remains eligible for the company’s standard executive benefit and severance programs. The company states he has no family relationships with directors or executive officers and no related‑party transactions requiring disclosure.
Becton, Dickinson and Company reported fiscal second-quarter 2026 revenue of $4.7 billion, up 5.2% year over year, driven by mid‑single‑digit growth across most businesses. U.S. revenue rose to $2.9 billion and international revenue to $1.8 billion.
From continuing operations, BD posted a GAAP diluted loss per share of $(0.13) versus earnings of $0.55 a year ago, reflecting higher integration, restructuring and other specified charges and the impact of discontinued operations. On an adjusted basis, diluted EPS from continuing operations was $2.90, up from $2.79.
BD executed a $2.0 billion accelerated share repurchase program and retired $2.1 billion of debt during the quarter. After completing the spin-off of its Biosciences and Diagnostic Solutions business, BD reaffirmed its full‑year 2026 revenue growth outlook and raised its adjusted diluted EPS guidance to a range of $12.52 to $12.72.
Becton, Dickinson and Company reported fiscal second-quarter 2026 revenue of $4.7 billion, up 5.2% year over year, driven by mid‑single‑digit growth across most businesses. U.S. revenue rose to $2.9 billion and international revenue to $1.8 billion.
From continuing operations, BD posted a GAAP diluted loss per share of $(0.13) versus earnings of $0.55 a year ago, reflecting higher integration, restructuring and other specified charges and the impact of discontinued operations. On an adjusted basis, diluted EPS from continuing operations was $2.90, up from $2.79.
BD executed a $2.0 billion accelerated share repurchase program and retired $2.1 billion of debt during the quarter. After completing the spin-off of its Biosciences and Diagnostic Solutions business, BD reaffirmed its full‑year 2026 revenue growth outlook and raised its adjusted diluted EPS guidance to a range of $12.52 to $12.72.
Becton Dickinson & Co. is reported as having 21,397,756 shares beneficially owned by Vanguard Capital Management as of 03/31/2026, equal to 7.51% of common stock. Vanguard Capital Management discloses sole dispositive power over 21,397,756 shares and sole voting power over 2,907,146 shares. The filing states these holdings include securities held for Vanguard funds and other managed accounts; no single other person is reported to hold more than 5% of the class.